Newsletter on Asthma Research: September-2018

A Decades-Old Asthma Drug Has Reversed Brain Damage From Dementia in Mice

Scientists have used a mice model to reverse a number of the foremost severe injury done to the brain by insanity – and that they did this with an astonishingly recent medication generally used for respiratory illness.

The discovery might open up the road for treatments that would restore memory and spacial impairment in folks with conditions like Alzheimer’s. whereas somebody’s treatment remains a way off, the analysis shows one methodology we tend to might use to retroactively treat the buildup of letter proteins, long thought to be a key consider insanity. [1]

Annexin A5 Protein as a Potential Biomarker for the Diagnosis of Asthma

Purpose: Annexin A5 (ANXA5) features a potential role in cellular signal transduction, inflammation, and pathology. However, the precise role of ANXA5 in respiratory illness remains to be processed. The aims of the current study were to research ANXA5 supermolecule expression in a very mouse model of {asthma|asthma attack|bronchial respiratory illness|respiratory disease|respiratory illness|respiratory disorder} and waste matter exposure and to elucidate the relationships between clinical variables and plasma ANXA5 levels in patients with asthma.

Methods: A murine model of respiratory illness iatrogenic by fixings (OVA) and titania (TiO2) nanoparticles has been established mistreatment BALB/c mice, and that we examined the ANXA5 expression and respiratory organ pathology mistreatment this model. Moreover, we tend to conjointly compare ANXA5 plasma levels in patients with controlled vs. exacerbated respiratory illness. [2]

Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma

Background: Real‐world evidence is sparse on the benefits of allergen immunotherapy [AIT; subcutaneous/sublingual immunotherapy (SCIT/SLIT)], the only disease‐modifying intervention for allergic rhinitis (AR) with long‐term efficacy. This real‐life study evaluated the effect of 6 AITs (native pollen SLIT/SCIT, four allergoid SCITs) versus symptomatic medication use, on AR symptoms and respiratory disorder symptoms/onset, in patients with birch pollen‐associated AR and/or asthma.

Methods: during this retrospective cohort analysis of a German longitudinal prescription info, AIT patients received ≥2 successive seasonal treatment cycles; non‐AIT patients had ≥3 AR prescriptions in 3 seasons or previous month. [3]

A Charter to Improve Patient Care in Severe Asthma

The severe respiratory disorder may be a subtype of asthma that’s tough to treat and manage. By conservative estimates, the severe respiratory disorder affects just about 5–10% of patients with asthma worldwide. Severe respiratory disease impairs patients’ health-related quality of life, and patients area unit in danger of critical respiratory disease attacks. Severe respiratory disorder additionally accounts for the bulk of health care expenditures related to asthma. pointers advocate that patients with severe respiratory disease be said a specialist metabolism team for proper diagnosing and professional management. this is often notably necessary to make sure that they need access to fresh accessible biological treatments. However, several patients with the severe respiratory disorder will suffer multiple asthma attacks and wait many years before they’re referred for specialist care. [4]

STUDY ON THE EFFECT OF INHALED CICLESONIDE ON SYSTEMIC INFLAMMATION IN BRONCHIAL ASTHMA

Introduction: The impact of Ciclesonide on general inflammatory and allergic markers equivalent to C reactive supermolecule (CRP) and IgE has to be evaluated once given in therapeutic doses to patients of asthma.

Aims and Objectives: to judge the impact of inhaled  Ciclesonide on general inflammatory [CRP, red blood cell erythrocyte sedimentation rate (ESR)], allergic [Absolute leucocyte Count (AEC), body fluid leucocyte Count (SEC), IgE] in asthma.

Methods: The on top of parameters were assessed in twenty new patients of delicate and moderate asthma WHO had not received inhaled or oral steroids throughout the past three months. Ciclesonide (160 mcg) was given once daily for 6weeks. All parameters were recurrent at the finish of the study. [5]

Reference

[1] A Decades-Old Asthma Drug Has Reversed Brain Damage From Dementia in Mice

DAVID NIELD, 12 JUN 2018 (web link)

[2] Annexin A5 Protein as a Potential Biomarker for the Diagnosis of Asthma

Lee SH, Lee PH, Kim BG, Hong J, Jang AS. Annexin A5 Protein as a Potential Biomarker for the Diagnosis of Asthma. Lung. 2018:1-9. (web link)

[3] Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma

Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma. Allergy. (web link)

[4] A Charter to Improve Patient Care in Severe Asthma

Menzies-Gow A, Canonica GW, Winders TA, de Sousa JC, Upham JW, Fink-Wagner AH. A Charter to Improve Patient Care in Severe Asthma. Advances in Therapy. 2018:1-2. (web link)

[5] STUDY ON THE EFFECT OF INHALED CICLESONIDE ON SYSTEMIC INFLAMMATION IN BRONCHIAL ASTHMA

BALAKRISHNAN MENON1*, RAJNISH KAUSHIK1, AND CHARANJEET KAUR2

1Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, India.

2Deaprtment of Biochemistry, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. (web link)